Eden Biodesign Ltd. and Selexis have expended their collaboration via a joint marketing partnership, which will provide global biopharma companies access to their services for the development of monoclonal antibodies and recombinant proteins derived from mammalian cell culture.

“We are very happy to be able to formally announce our relationship with Selexis and their extremely powerful approach to the development of high-productivity cell lines, which we are able to offer to our clients,” said Dr. Roger Lias, president of Eden Biodesign’s U.S. subsidiary and group commercial director. “We recognize the vital importance of speed-of-development and of attractive final cost-of-goods for biopharmaceuticals. Working with our colleagues at Selexis provides the opportunity for our mutual clients to achieve both.”

“The relationship with Eden has enabled a number of mutual clients the ability to progress rapidly from DNA to cGMP manufacturing with a cost effective manufacturing platform, without sacrificing performance or quality,” said Andrew Sandford, vice president of business development for Selexis’ U.S. subsidiary. “At Selexis we appreciate the efforts associated with cGMP manufacturing and are pleased to recommend Eden to our clients as an ideal option for cGMP manufacturing.”

Eden Biodesign provides biopharma, vaccine process development, and cGMP manufacturing services. The company also offers clients consultant services. Selexis offers technologies and services for the rapid development of high-performance, stable mammalian cell lines. Its SURE Cell Line Development Platform generates high producing cell lines in five weeks, according to the company.